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A B S T R A C T
Pregnancy requires a special management in women with inflammatory rheumatic diseases (RDs), with the aim
of controlling maternal disease activity and avoiding fetal complications. Despite the heterogeneous course of
RDs during pregnancy, their impact on pregnancy largely relates to the extent of active inflammation at the time
of conception. Therefore, accurate evaluation of disease activity is crucial for the best management of pregnant
patients. Nevertheless, there are limitations in using conventional measures of disease activity in pregnancy, as
some items included in these instruments can be biased by symptoms or by physiological changes related to
pregnancy and the pregnancy itself may influence laboratory parameters used to assess disease activity. This
article aims to summarize the current literature about the available instruments to measure disease activity
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during pregnancy in RDs. Systemic lupus erythematosus is the only disease with instruments that have been
modified to account for several adaptations which might interfere with the attribution of signs or symptoms to
disease activity during pregnancy. No modified-pregnancy indices exist for women affected by other RDs, but
standard indices have been applied to pregnant patients.
The current body of knowledge shows that the physiologic changes that occur during pregnancy need to be
either adapted from existing instruments or developed to improve the management of pregnant women with
RDs. Standardized instruments to assess disease activity during pregnancy would be helpful not only for clinical
practice but also for research purposes.
1. Introduction
Rheumatic diseases (RDs) often affect women during childbearing
age. Planning a family is now a reality for these women, thanks to
earlier diagnosis and improved management of RDs. Pregnancy is a
delicate period that needs a special management to control the ma-
ternal disease and to avoid complications for both the mother and the
fetus. The management of RDs during pregnancy should aim at mini-
mizing the effects of maternal disease on pregnancy outcome.
Rheumatoid arthritis (RA) and chronic inflammatory arthritis, such
as polyarticular juvenile idiopathic arthritis (JIA), tend to improve
spontaneously during pregnancy in the majority of patients [1], even
though less frequently than described in the past [2]. Spondyloarthritis
(SpA) tend to be stable or to get worse during pregnancy, even though
the available literature is scarce [1]. Systemic lupus erythematosus
(SLE) can flare up to 50% of pregnancies, including a major organ in-
volvement in nearly 25% of the cases [1]. The effect of other connective
tissue diseases (CTD) on pregnancy or vice versa has been less in-
vestigated. A special consideration should be given to anti-phospholipid
syndrome (APS) because one of its main clinical manifestations are
pregnancy complications. Pregnancy does not seem to worsen the ac-
tivity of systemic vasculitis, but a disease flare during pregnancy can
lead to severe complications [3].
Active disease or flares during pregnancy can negatively impact
fetal health and pregnancy outcome [4]. Therefore, accurate evaluation
of disease activity is crucial for the best management of these patients.
However, there are limitations in using conventional measures of dis-
ease activity in pregnancy, as some items from these instruments can be
biased by symptoms or by physiological changes related to pregnancy
and pregnancy itself may influence laboratory parameters [5]. In par-
ticular, some laboratory investigations have to be interpreted with
caution: mild anemia, mild thrombocytopenia, proteinuria, and in-
creased erythrocyte sedimentation rate (ESR) are common during
pregnancy. Complement levels become less informative with the in-
crease in levels during normal pregnancy and renal function should be
interpreted considering the physiological increased plasma volume and
glomerular filtration rate. Pregnancy can cause skin manifestations,
mild knee effusion and low back pain that can interfere with the eva-
luation of disease activity.
Most of the studies on this subject have focused on SLE and RA.
However, different instruments and definitions of remission or flares
were used, making it difficult to compare different cohorts. It clearly
emerges that valid measures of disease activity during gestation are of
pivotal importance. The paucity of documentation and the lack of
standardization make this a focal point to review.
The aim of this narrative review is to summarize the scientific lit-
erature available on instruments to assess disease activity during
pregnancy in different RDs.
2. Measurement of disease activity in pregnant patients with
rheumatic diseases
2.1. Rheumatoid arthritis
Women have a three-fold higher risk of developing RA than men,
and the number of patients experiencing a pregnancy has sig-
nificantly expanded over the last two decades, polarizing a growing
attention on reproductive health matters [6]. An active disease
during pregnancy has been clearly demonstrated to increase the risk
of preterm delivery and placental insufficiency leading to low birth
weight, while the association of pre-eclampsia (PE) and gestational
hypertension with active RA is still debated [7,8]. Hench, back in
1938, was the first author to describe the ameliorating effects of
pregnancy on RA [9]. This observation was confirmed by following
early studies, all concordant in reporting high rates of disease im-
provement or remission during gestation (Table 1). Unfortunately,
these findings were to be downsized in forthcoming years: it is now
well ascertained that RA improves during pregnancy, but to a much
lower extent than what was believed in pioneering times. The ex-
planation of such striking difference should be ascribed to the fact
that early reports had a retrospective design, assessed disease ac-
tivity heterogeneously, often relying on the amelioration of symp-
toms reported by patients. Furthermore, in modern rheumatology an
optimal disease control can be reached, thus limiting the ameliora-
tive potential of pregnancy. However, no modified pregnancy dis-
ease activity index has been developed in RA. Studies in the field
have investigated a number of different parameters: ESR, C reactive
protein (CRP), clinical examination, self-reported activity measures,
or clinimetric indices commonly used in clinical practice including
visual assessment scale (VAS), disease activity score (DAS28), health
assessment questionnaire (HAQ), short-form 36 (SF-36) [10]. As
mentioned above, pregnancy itself can potentially affect several of
these parameters: ESR physiologically increases during gestation,
while fatigue, anemia and arthralgias are quite common in preg-
nancy, potentially influencing VAS and global health (GH) [11].
Moreover, physical changes related to pregnancy, such as weight
gain, can impact functional abilities included in HAQ [11]. Few
studies have assessed the performance of the common clinimetric
indices during gestation. To note, many studies are from the Dutch
Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA)
cohort, which might cause a bias for duplication of data (Table 1).
De Man demonstrated that a healthy pregnancy can influence dif-
ferent components of DAS28, with average score increase of 0.22 for
GH, 1.1 for ESR, and 0.25 for CRP. Consequently, DAS28-CRP3,
excluding the patient GH assessment, emerged as the best tool to
assess disease activity in pregnant RA women [11]. More recently,
the patient-administered Rheumatoid Arthritis Disease Activity
Index (RADAI) has been shown to correlate with DAS28-CRP3 in 32
pregnant RA patients, suggesting that this simple and fast ques-
tionnaire could represent a good option to assess disease activity in
pregnant RA women, at least outside a rheumatology clinic [12].
Interestingly, in 17 of these 32 patients, Clinical Disease Activity
Index (CDAI) was also performed: it correlated well with both
DAS28-CRP3 and RADAI, suggesting that CDAI could be useful even
during pregnancy [12]. Conversely, Simple Disease Activity Index
(SDAI) has never been validated in this setting and is not currently
used in RA pregnant women. At present DAS28-CRP3 is addressed as
the best clinimetric index to evaluate disease activity in pregnant RA
patients, but further studies are needed to define if an ad hoc mod-
ified activity score could perform better.
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2.2. Spondyloarthritis
SpA are a group of disorders including psoriatic arthritis (PsA) and
ankylosing spondylitis (AS) that share similar pathogenic and clinical
features [13]. During pregnancy, patients with SpA can experience either
an active disease or a stable/reduced disease activity. Recent studies in
small cohorts of SpA patients showed a disease flare during pregnancy in
25% of patients affected by axial SpA [14] while a reduced disease ac-
tivity was demonstrated in 70% of AS patients [15]. Several different
instruments have been proposed to measure diseases activity in SpA, as
unidimensional (focused on joint activity) and as multidimensional
(combining different domains) clinimetric indices [16,17]. However,
concerning pregnancy and childbearing, no modified indices for disease
activity exist for SpA. Standard clinimetric indices were used to measure
disease activity during pregnancy in patients affected by AS and PsA. The
Bath Ankylosing Spondylitis Activity Index (BASDAI) was used in a pro-
spective study in 9 pregnant women with AS. Higher disease activity
scores during the second trimester and a mitigation of symptoms in the
third trimester were observed. A good to moderate correlation between
most clinical measurements were shown, even if functional indices (in-
cluding bending), measures of pain and fatigue might be confounded by
physiological changes of late pregnancy [18].
Two retrospective studies [14,15] and one prospective study [19]
used the Ankylosing Spondylitis Disease Activity Score (ASDAS) during
pregnancy in 61 axial SpA patients and 20 AS pregnant women. ASDAS
was used to evaluate disease activity, flares and treatment response
during pregnancy. Lui and colleagues also evaluated night pain and
morning stiffness in 19 AS pregnant women; an improvement in these
parameters was registered in the first trimester while a worsening was
detected in the third trimester likely secondary to biomechanical
loading [20]. Concerning PsA, no robust data are available due to the
low sample size. However, women with psoriasis may encounter new-
onset psoriasis in addition to flares in 45% of the patients during
pregnancy, and in 65% up to 6 weeks postpartum; the clinimetric index
used was the Psoriasis Area and Severity Index (PASI) [21]. In a recent
study on 29 PsA women with 42 pregnancies, a worsening of joint and
skin activity was found in 31.7% and 42.9% respectively, during
pregnancy and in the first year after delivery. Joint disease was mea-
sured as the number of inflamed joints and based on the definition of
the Minimal Disease Activity (MDA) [22]. No modified-pregnancy in-
dices exist for women affected by SpA. Of note, several symptoms such
as lumbar night pain, morning stiffness and fatigue could be influenced
by pregnancy itself; therefore, disease activity might be overestimated
[18]. Moreover, the course of the SpA during pregnancy is extremely
variable with some data reporting an improvement and others a wor-
sening of the disease. In the field of SpA, several missing data emerged.
Composite clinimetric indices were never tested in SpA pregnant
women neither the impact on quality of life, by means of SF-36 or HAQ-
SpA, were evaluated in this population.
2.3. Juvenile idiopathic arthritis
JIA comprises a heterogeneous group of diseases, mainly char-
acterized by the presence of inflammatory arthritis with an onset before
16 years of age [23]. JIA is more frequent in females than in males and
in more than one third of patients the disease can persist in adulthood
[23]. The dramatic changes in the prognosis resulting from the in-
troduction of biological agents have increased the number of JIA female
patients experiencing a pregnancy [24]. However, very few studies
have assessed disease activity during gestation in JIA and no validated
clinimetric index is currently available. Ursin has recently described the
impact of pregnancy on disease activity in 114 women with JIA, using
DAS28-CRP3, modified HAQ (MHAQ) and SF-36 [25]. Given the ab-
sence of validated clinimetric scores for disease activity of JIA in
pregnancy, DAS28-CRP3 could represent a reliable activity index in a
disease, very similar to RA.
2.4. Systemic lupus erythematosus
In SLE patients, pregnancy is considered at high-risk and it is as-
sociated with an increased risk of flares, particularly in patients with
active disease at the time of conception [26]. Women with previous
lupus nephritis should be carefully managed for the risk of flare during
pregnancy and/or the onset of PE [27]. Therefore, a strict assessment
and a tight control of disease activity before and throughout pregnancy
is crucial; however, physiological changes in pregnancy may mimic a
lupus flare (e.g. constitutional symptoms, non-inflammatory joint pain,
skin rash, alopecia), as well as, laboratory changes (e.g. anemia,
thrombocytopenia, proteinuria, increase of ESR) [26]. There is in-
creasing interest in this topic, as the health conditions of children born
to mothers with SLE have been claimed to be possibly associated with
maternal disease activity during pregnancy [28] or to the transplacental
passage of maternal autoantibodies as in the case of anti-Ro/SSA anti-
bodies [29].
Established lupus activity scales, such as the Lupus Activity Index
(LAI), the SLE Disease Activity Index (SLEDAI) and the Systemic Lupus
Activity Measure (SLAM), were originally validated in SLE patients
excluding pregnant women. In order to reduce confounding features
from physiological pregnancy and SLE exacerbations, in 1999 the
members of the Systemic Lupus International Cooperating Clinics pro-
posed three modified-pregnancy scores: the SLE-Pregnancy Disease
Activity Index (SLEPDAI), the LAI in Pregnancy (LAI–P) and the mod-
ified SLAM (m-SLAM) [5]. More recently, two other pregnancy-adapted
scores have been introduced, the modified-European consensus lupus
activity measurement (m-ECLAM) [30] and the British Isles Lupus As-
sessment Group-2004 for pregnancy (BILAG2004-P) [31]. The main
features of each index are summarized in Table 2.
In the LAI–P, proposed by Khamashta and Ruiz-Irastorza [5], the
VAS from the original version was replaced with a graded scale. Some
items in the original LAI were excluded (e.g. patient global assessment
(PGA) and fatigue) to avoid pregnancy related symptoms to be scored
as disease activity and other more objective terms, such as “vasculitis,”
“fever,” or “myositis,” were added [32]. The relative weight of every
item has also been modified. Manifestations related to APS, such as
cerebrovascular accidents or thrombocytopenia, were not scored in LAI-
P in patients with antiphospholipid antibodies (aPL) unless other signs
of lupus activity were present. The LAI-P includes 4 groups: Group 1
(fever, rash, arthritis and serositis); Group 2 (neurologic, renal, lung,
hematologic, vasculitis and myositis); Group 3 (prednisone/NSAIDs/
hydroxychloroquine (HCQ) and immunosuppressants) and Group 4
(proteinuria, anti-DNA, and C3/C4). The LAI–P, validated in 2004 [29],
has been recently used to explore the associations between disease
activity and medications with offspring birth weight, PE and preterm
birth in Swedish pregnant women with SLE [33].
In SLEPDAI, 15 out of the 24 original items of the SELENA-SLEDAI
were modified [5]. The 15 items that should be carefully examined
before scoring are: seizure, headache, cerebral infarction, cranial nerve
disorder, vasculitis, arthritis, hematuria, proteinuria, pyuria, rash,
alopecia, pleurisy, low complement levels, thrombocytopenia, and
leukopenia. To be considered as a flare of lupus, some pregnancy-re-
lated physiological changes must be ruled out, including: 1) PE/
eclampsia (E), and Bell's palsy when considering neurologic involve-
ment; 2) the presence of isolated microscopic hematuria, mild protei-
nuria (< 500mg/24 h), and/or pyuria (also common in urinary tract or
vaginal infections) when considering renal involvement; 3) bland joint
effusions, frequent during pregnancy; 4) melasma, transient nonspecific
facial blush, palmar erythema, and postpartum alopecia when con-
sidering cutaneous involvement; 5) mild resting dyspnea before con-
sidering pleurisy; 6) PE/E, HELLP (hemolysis elevated liver enzymes
low platelet count) syndrome, incidental thrombocytopenia, abruption
placentae, fetal demise, and aPL should be considered when there is
hematologic involvement such as thrombocytopenia [5]. SLEPDAI has
not been formally validated, although it has been used in three studies,
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two of which were designed to assess the effect of HCQ on SLE ex-
acerbations in pregnant women [34,35] and one more recent evaluating
the complement activation as a predictor of adverse pregnancy outcome
in patients with SLE [36].
In 1995, a modification of SLAM-R, the m-SLAM, was proposed by
Ramsey-Goldman and colleagues [37]. Some items were eliminated
from SLAM-R, such as weight loss, ESR, and the ad hoc scale for mis-
cellaneous disease manifestations [37]. Several descriptors, such as
fatigue, myalgia, arthralgia, gastrointestinal symptoms, lymphadeno-
pathy, hepatosplenomegaly, Raynaud's phenomenon, and hypertension,
that are not addressed in the SLEPDAI and LAI–P, are included in the m-
SLAM [5].
In two prospective studies published in 2002 [30] and 2004 [38]
Doria et al. used a modified version of ECLAM, the m-ECLAM. Three of
the original 15 items were changed as follows: 1) proteinuria con-
sidered pathological if ≥500mg/day and after excluding PE; 2) non-
hemolytic anemia was not considered due to its high frequency during
pregnancy; and 3) ESR was not considered due to its physiological in-
crease during pregnancy [30].
In 2012, the BILAG2004-P index was introduced by Yee and col-
leagues [31]. The major modification was in the assessment of renal
involvement: complement levels (C3 and C4) and anti-dsDNA were
added to differentiate proteinuria due to lupus nephritis from PE and
hypertension was omitted from the index [31]. Similarly to other in-
dices, the glossary also changed to remind the physician of the con-
founding items during pregnancy.
In all the above-mentioned indices, modifications were made to
address influential items: some were eliminated (e.g. ESR, asthenia) and
others were adapted to physiological pregnancy changes (e.g. protei-
nuria levels), emphasizing the need to differentiate those changes from
pregnancy comorbidities (e.g. PE/E). The scoring of each index is cal-
culated in the same way as the original version, except for the LAI–P, in
which the weighted score given to each item has been modified. Even
though many attempts have been made to develop a pregnancy-specific
disease activity index that can be reliable and valid in measuring dis-
ease activity, the clinical judgment of an experienced physician remains
the gold standard in the management of pregnant women with SLE. As
recently recommended [39], these women should be frequently mon-
itored (every 2 to 8 weeks) and during each visit the PGA in conjunction
with at least one of the activity tools and pregnancy-specific SLE ac-
tivity indices (such as SLEPDAI, LAI–P, BILAG 2004-P) should be ap-
plied.
2.5. Anti-phospholipid syndrome
The assessment of disease activity in APS is different compared to
other RDs. As already mentioned, APS can present thrombosis and/or
pregnancy complications, as main clinical manifestations. No clini-
metric indices exist for APS, but a scoring system has been developed to
predict the risk of thrombosis (either first or recurrent) and pregnancy
morbidity [40]. Studies in pregnant women with APS, used the occur-
rence or recurrent of arterial or venous thrombosis, pregnancy com-
plications and non-criteria APS manifestations to assess the disease
course during pregnancy [41,42].
2.6. Other connective tissue diseases
2.6.1. Undifferentiated connective tissue disease
Undifferentiated connective tissue disease (UCTD) is a rheumatic
disease with combination of signs and symptoms of connective tissue
disease, that does not fulfill criteria for a major CTD. Pregnancies in
UCTD have been described and many studies have investigated preg-
nancy outcome [43]. The evaluation of disease course during preg-
nancy has also been assessed. Mosca et al. studied a population of 20
UCTD patients during their 25 pregnancies to investigate disease flare
during pregnancy, pregnancy course and to determinate if pregnancy
could be a trigger for disease evolution to a defined CTD. Flare in UCTD
was defined as a disease activity increase based on physician's assess-
ment and on therapeutic changes [44]. Also, Castellino et al. studied the
outcome of 55 pregnancies in 50 UCTD patients followed during
pregnancy and 6months after delivery; maternal outcome was also
investigated to detect disease relapse or differentiation into defined
CTD comparing the ouctome of pregnant patients with a control-po-
pulation of 53 non-pregnant UCTD followed for 16months. Disease
flare was based on clinical judgment: new onset or worsening of pre-
existing symptoms and/or treatment modifications [45]. So, at present,
no validated indices have been proposed to assess disease activity in
UCTD patients and clinical judgment still is the gold standard for both
pregnant and non-pregnant patients.
2.6.2. Mixed connective tissue diseases
Mixed connective tissue disease (MCTD) is an autoimmune CTD
characterized by an overlap syndrome with features of lupus, scler-
oderma, and poly/dermatomyositis (PM/DM), in patients who carry
positivity for anti-U1 ribonucleoprotein (RNP) autoantibodies. Patients
may exhibit manifestations of any of the composing diseases during the
course of the disease [46].
MCTD primarily affects women during the years of childbearing
potential [47]; their fertility rates seem to be similar to adjusted age-
matched controls. A small number of MCTD cases showed its onset
during pregnancy, and definite MCTD have been reported having flares
during gestation: a worsening or new onset of clinical manifestations
(e.g. worsening of interstitial lung disease, arthritis) were used to de-
scribe a disease flare [48–52]. A study focusing on MCTD pregnancy
outcome [53] reported a case of a pregnant patient affected by pul-
monary arterial hypertension (PAH). The patient was clinically stable,
as monitored by six minutes walking test before and during the preg-
nancy. To date, no validated indices exist to assess disease activity in
pregnant and non-pregnant women with MCTD.
2.6.3. Inflammatory myopathies
DM and PM are autoimmune inflammatory myopathies (IM) char-
acterized by proximal symmetric muscle weakness and, in case of DM, a
large variety of skin manifestations [54]. As other autoimmune dis-
eases, they predominantly affect female gender [55]. Since the two
peaks of IM onset are in childhood and over the age of 45 years, women
in reproductive age group are uncommonly affected [54]. Indeed, the
proportion of IM onset from 25 to 34 years is estimated to be 4–11%
[56]. As a consequence, pregnancies in patients affected with IM are
rare.
To date, two international collaborative groups, the International
Myositis Assessment and Clinical Studies Group (IMACS) and the
Paediatric Rheumatology International Trials Organisation (PRINTO),
have defined consensus core set measures to assess myositis disease
activity and damage in adults and children and have begun to validate
and standardize these measures [57,58].
No recommendations on how to assess IM activity and damage
during pregnancy have been done, given the small sample size of the
few relevant studies. Thus, the optimal assessment of pregnancy out-
come and disease activity in IM patients during pregnancy remains
elusive.
IM activity has been defined in some studies by the presence of any
rash, muscle weakness and elevation of muscle serum enzymes [59].
Cutaneous manifestations included Gottron papules and heliotrope
rash, whereas serum muscle enzymes consist in elevation of creatine-
kinase (CK) and/or lactate dehydrogenase (LDH) [60].
A recent study [60] assessed disease activity in pregnant patients by
performing both the UK Medical research council system scale (0–5)
and the manual muscle strength testing (MMT).
Therefore, the clinimetric indices for IM should be further in-
vestigated during pregnancy.
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2.6.4. Sjögren's syndrome
Sjögren's syndrome (SS) is an autoimmune systemic disease char-
acterized by dysfunction of exocrine glands and possible multiorgan
involvement. Disease activity indices have been created to evaluate two
different aspects of the disease: patient's symptoms and systemic ac-
tivity. Different indices were proposed in the past to assess disease
activity but currently no indices have been modified and validated for
pregnant SS patients. Many studies have investigated the interaction
between SS and pregnancy, but they all focused on pregnancy outcome
[61,62]. Only one study by Priori et al. investigated maternal disease
during pregnancy and one year post-partum. In this study, no disease
activity index was used to assess disease, but flares were defined as the
onset or worsening of symptoms leading to therapeutic changes [63].
2.6.5. Systemic sclerosis
Systemic sclerosis (SSc) is a really unpredictable disease. Even if
studies published during the last years demonstrated that the majority
of women with SSc do not undergo significant modifications of disease
activity during pregnancy, neither have worsening of symptoms after
delivery [49,64–66], there is a risk of worsening of the disease for some
SSc women who have organ involvement such as lungs, heart, and
kidneys [66]. Thus, a close monitoring of internal organs and skin in-
volvement, blood pressure and monthly blood tests is mandatory. Until
today, there are no validated indices to analyze disease activity, se-
verity and outcome during pregnancy, so that all the studies conducted
till now just considered disease progression as changes in organ in-
volvement [64,65,67,68]. Indeed, the definition of disease activity in
SSc pregnancy cannot be done using a single variable and the disease
activity indices proposed in the literature (the European Scleroderma
Study Group (EScSG) activity index, the 12-point DAI, EUSTAR activity
index, and the Combined Response Index for Systemic Sclerosis
(CRISS)) are preliminary or provisional, not fully validated and not
used in studies on pregnancy [69–71]. In the IMPRESS 1 study, a
Medsger severity score > 2 in at least 1 item and changes in organ
involvements and laboratory exams were used to assess the maternal
outcomes in pregnant SSc women [65].
2.7. Systemic vasculitis
Most of the literature focuses on pregnancies in women with Behçet
disease (BD) and Takayasu arteritis (TA) because of the earlier median
age of onset, however, cases of pregnancy during antineutrophil cyto-
plasmic antibody (ANCA)–associated vasculitis (AAV) have also been
reported in the literature.
AAV are small-vessel, necrotizing vasculitis primarily affecting the
respiratory tract, lungs, kidney, and peripheral nervous system [72]. At
present, there is no specific clinical instrument to assess AAV disease
activity during pregnancy. In the majority of the studies performed in
AAV pregnant patients, disease activity was scored using the Bir-
mingham Vasculitis Activity Score (BVAS) [73] whilst damage due to
vasculitis was scored by the Vasculitis Damage Index (VDI) [74]; fur-
thermore, most studies collected the characteristics of the patients (age,
type of AAV, organ involvement, ANCA status, ongoing and previous
treatment), maternal outcomes (renal function, arterial hypertension,
PE), fetal and neonatal outcomes (fetal growth restriction (FGR), pre-
maturity, birth weight, perinatal mortality), type of delivery [75–83].
In the majority of reported cases, women with AAV in remission had a
favorable maternal and neonatal outcome with quiescent disease or
Table 3
Disease activity indices used in clinical studies involving pregnant women with Rheumatic diseases.
Rheumatic diseases Modified pregnancy
indices
Standard indices used in studies during pregnancy Other outcome measures used in studies during pregnancy
RA – DAS28-CRP3; RADAI; DAS28-ESR or CRP4; CDAI Self-reported joints; morning stiffness; Reported joint symptoms and/or
treatment modification
AS – BASDAI; ASDAS –
PsA – ASDAS; PASI; MDA Worsening of joint activity and worsening of skin activity (Physician's
Judgment)
JIA – DAS28-CRP3 –




SLEDAI; PGA Clinical and laboratory assessment and/or treatment modification
(Physicians Judgment)
APS – – –
UCTD – – Worsening or new onset of clinical manifestations and/or treatment
modification (Physician's Judgment)
MTCD – – Worsening or new onset of clinical manifestations and/or treatment
modification (Physician's Judgment)
DM – UK medical research council system scale; MMT Cutaneous manifestations (Gottron's papules, heliotrope rash) (Physician's
Judgment) and elevated muscle enzymes levels (CK, LDH)
PM – UK medical research council system scale; MMT –
SS – – Worsening or new onset of clinical manifestations and/or treatment
modification (Physician's Judgment)
SSc – Medsger severity score > 2 (in at least 1 item and
changes in organ involvement)
–
AAV – BVAS; VDI Typical complications: respiratory, cutaneous, articular, renal
TakA – Kerr/NIH index Two new-onset or worsening items in the previous 3months
BD – – Onset of new clinical manifestations or increased frequency of symptoms
requiring treatment changes (Physician's Judgment)
Legend- A/V: arterial/venous; AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; APS: antiphospholipid syndrome; AS: ankylosing
spondylitis; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Activity Index; BD: Behçet disease; BILAG2004-P: British
Isles Lupus Assessment Group-2004 for pregnancy; BVAS: Birmingham Vasculitis Activity Score; CDAI: clinical disease activity index; CK: creatine kinase; DAS28-
CRP3: disease activity score 28 joints count-C reactive protein; DAS28-ESR: disease activity score 28 joints count-erythrocyte sedimentation rate; JIA: juvenile
idiopathic arthritis; LAI–P: Lupus Activity Index in Pregnancy; LDH: lactate dehydrogenase; m-ECLAM: modified-European consensus lupus activity measurement; m-
SLAM: modified Systemic Lupus Activity Measure; MDA: Minimal Disease Activity; NIH: National Institutes of Health; PASI: Psoriasis Area and Severity index; PGA:
Patients Global Assessment; PsA: psoriatic arthritis; RA: rheumatic arthritis; RADAI: rheumatoid arthritis disease activity index; SLE: systemic lupus erythematosus;
SLEDAI: SLE Disease Activity Index; SLEPDAI: SLE-Pregnancy Disease Activity Index; SS: Sjögren syndrome; SSc: systemic sclerosis; TakA: Takayasu arteritis; UCTD:
undifferentiated connective tissue disease; UK: United Kingdom; MMT: manual muscle strength testing; VDI: Vasculitis Damage Index.
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only minor glucocorticoids-dose adjustment; conversely, outcomes
were poorer when pregnancies were conceived during active disease or
when AAV started during pregnancy [3,75–86]. The most frequent
complications were respiratory, cutaneous, articular and renal flares,
arterial hypertension, PE, prematurity [3,75–86]. By using BVAS during
pregnancy, great attention should be paid to the evaluation of renal,
central nervous system and constitutional symptoms that can be con-
founded by physiological (e.g. proteinuria) or pathological changes
(e.g. PE). The item “ischemic abdominal pain” deserves a special
mention because it can mimic the abdominal pain during PE.
TA is a large vessel vasculitis primarily affecting aorta and its major
branches [87]. At present, a validated clinical instrument to assess TA
disease activity in pregnancy does not exist. Some studies in pregnant
TA patients used the Kerr/NIH index [88,89] that assesses four items:
constitutional manifestations, raised ESR, manifestations of vascular
ischemia, angiographic features indicative of vasculitis: disease is de-
fined as active in case of at least two new or worsened items in the
previous three months. Nevertheless, items such as ESR and muscu-
loskeletal symptoms can be influenced by pregnancy, so they should be
interpreted with caution. Furthermore, most of the studies
[3,84,88–93] took into account the general characteristics of the sub-
jects (age, type of arterial involvement, parity, previous obstetric
complications), maternal outcomes (glucocorticoid dose increase, CRP
and ESR, arterial hypertension, PE, renal and cardiac failure, cardio-
vascular events), fetal and neonatal outcomes (FGR, prematurity, birth
weight, perinatal mortality, Apgar score at 5min) [3,84,88–95].
Pregnancy does not seem to affect disease activity in TA patients
[80], nevertheless, maternal complications such as sustained hy-
pertension, PE, congestive heart failure and cerebrovascular accidents
are not uncommon [3,84,88–96].
BD is a multisystemic disorder of unknown etiology characterized
by mucocutaneous, ocular, vascular, and central nervous system man-
ifestations [97]. No validated indices assessing BD disease activity in
pregnancy are currently available. Disease flares were usually defined
as the onset of new symptoms or increased frequency of symptoms
requiring treatment changes during pregnancy. Studies on BD preg-
nancies also evaluated patient's characteristics (age, organ involvement,
ongoing and previous treatment), maternal outcomes (arterial hy-
pertension, PE, glucocorticoid dose increase), and fetal/neonatal out-
comes (prematurity, low birth weight, perinatal mortality, neonatal
intensive care unit admission) [3,84,97]. Pregnancy does not seem to
affect disease activity; only around one third of reported cases experi-
ences relapse, primarily with mucocutaneous and ocular manifestations
[85,98–100]. In the majority of reported cases, women with BD had
pregnancy outcomes similar to those seen in general population even
though complications as preterm birth, pregnancy loss, and thrombotic
events during pregnancy and puerperium have also been reported
[101–104].
3. Conclusions
The physiologic and pathological changes that occur during preg-
nancy need to be reflected in existing instruments for non-pregnant
patient with RDs (Table 3).
To date, SLE is the only disease with modified-pregnancy indices.
Five commonly utilized instruments have been modified to account for
several adaptations which might confound the attribution of signs or
symptoms to disease activity: SLEPDAI, LAI–P, m-SLAM, m-ECLAM and
BILAG2004-P.
No modified-pregnancy indices exist for women affected by other
RDs. In RA, JIA, SpA and Systemic Vasculitis standard validated indices
have been used to assess disease activity in pregnant woman. The
DAS28-CRP3 resulted as the best instrument to evaluate disease activity
in pregnant RA patients. In other RDs without a validated clinimetric
index to assess disease activity, such as SS, MCTD, UCTD, and SSc,
studies in pregnant women are scarce and the evaluation of disease
activity is still based on the physician's judgment.
Therefore, there is a need to develop modified-pregnancy clini-
metric indices to ensure continuity of assessments when RDs patients
become pregnant in long-term longitudinal studies. Furthermore, con-
sistent use of a standardized and validated disease activity outcome
measure in the assessment of pregnant RDs patients may help address
the scarce and, sometimes, conflicting reports of the effects of preg-
nancy on exacerbation of RDs.
The elaboration and standardization of measure to assess disease
activity in pregnant women with RDs will enable us to improve the
accuracy of advice to women during pregnancy and to develop better
management protocols.
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